Valuation : Recursion Pharmaceuticals, Inc.

Market Cap 1.79B 1.54B 1.45B 1.32B 2.48B 169B 2.5B 17.13B 6.67B 86.21B 6.7B 6.56B 286B P/E 2026 *
-3.8x
P/E 2027 * -3.87x
Enterprise Value 1.4B 1.21B 1.13B 1.03B 1.94B 133B 1.95B 13.41B 5.22B 67.5B 5.25B 5.14B 224B EV / Sales 2026 *
32.8x
EV / Sales 2027 * 27.7x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
1 day-1.05%
1 week-6.46%
Current month-2.06%
1 month+11.00%
3 months-12.14%
6 months-9.26%
Current year-18.58%
1 week 3.25
Extreme 3.25
3.55
1 month 2.92
Extreme 2.92
3.63
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
7.18
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
29.4
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 2025-12-31
Director of Finance/CFO 48 2024-11-19
Chief Tech/Sci/R&D Officer 57 2026-04-05
Director TitleAgeSince
Director/Board Member 44 2013-11-03
Director/Board Member 62 2013-11-03
Director/Board Member 37 2016-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Tax

Chief Technology Officer

-26,657 0.0051%
8/17/26 Tax

Chief Executive Officer

-80,498 0.0153%
8/17/26 Tax

Chief Financial Officer

-25,018 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%-6.46%-29.15%-63.49% 1.79B
-0.25%-4.10%+38.38%+92.61% 68.21B
+1.31%+0.02%+48.15%+89.05% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.42%+0.56%+31.42%-18.48% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.65%-5.28%-1.12%+534.90% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average -0.01%-4.18%+38.01%+177.12% 26.49B
Weighted average by Cap. +0.21%-3.25%+41.25%+157.18%

Financials

2026 *2027 *
Net sales 42.68M 36.82M 34.63M 31.55M 59.33M 4.05B 59.65M 409M 159M 2.06B 160M 157M 6.83B 56.25M 48.52M 45.64M 41.58M 78.19M 5.34B 78.62M 540M 210M 2.72B 211M 207M 9B
Net income -459M -396M -372M -339M -638M -43.54B -641M -4.4B -1.71B -22.15B -1.72B -1.69B -73.44B -474M -409M -385M -351M -659M -45.02B -663M -4.55B -1.77B -22.9B -1.78B -1.74B -75.93B
Net Debt -388M -334M -314M -286M -539M -36.78B -542M -3.72B -1.45B -18.71B -1.45B -1.42B -62.03B -227M -196M -184M -168M -315M -21.51B -317M -2.17B -846M -10.94B -851M -833M -36.29B
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26-09-01 US$3.330 -2.06% 9,996,546
26-08-31 US$3.400 +1.80% 13,911,889
26-08-28 US$3.340 -2.91% 10,560,576
26-08-27 US$3.440 -1.43% 10,986,829
26-08-26 US$3.490 -1.97% 12,978,424
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.330USD
Average target price
7.217USD
Spread / Average Target
+116.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RXRX Stock